BiotechTube

Dovitinib (TKI258)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenoid Cystic Carcinoma

Conditions

Adenoid Cystic Carcinoma

Trial Timeline

Mar 1, 2012 → Dec 1, 2015

NCT ID
NCT01524692

About Dovitinib (TKI258)

Dovitinib (TKI258) is a phase 2 stage product being developed by Novartis for Adenoid Cystic Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01524692. Target conditions include Adenoid Cystic Carcinoma.

What happened to similar drugs?

1 of 2 similar drugs in Adenoid Cystic Carcinoma were approved

Approved (1) Terminated (0) Active (1)
✅mometasone furoate nasal sprayOrganonApproved
🔄Mometasone Furoate nasal spray + PlaceboOrganonPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01831726Phase 2Completed
NCT01524692Phase 2Completed
NCT01478373Phase 2Completed

Competing Products

11 competing products in Adenoid Cystic Carcinoma

See all competitors
ProductCompanyStageHype Score
Enfortumab VedotinAstellas PharmaPhase 2
42
LenvatinibEisaiPhase 2
39
Lenvatinib + PembrolizumabEisaiPhase 2
39
P-SamAstraZenecaPhase 2
42
CetuximabMerckPhase 1/2
28
PembrolizumabMerckPhase 2
35
DovitinibNovartisPhase 2
35
AG-013736 (AXITINIB)PfizerPhase 2
35
RegorafenibBayerPhase 2
32
Mometasone Furoate nasal spray + PlaceboOrganonPhase 3
34
mometasone furoate nasal sprayOrganonApproved
37